May 26, 2026 03:24 PM seekingalpha.com Positive

Russell 3000 Shuffle: Ocugen, Nektar slated to join among healthcare stocks; Nano-X to drop off

AGEN CRDF CTMX FATE NKTR NNOX OCGN QSI SENS TVRD

[Health Care sector, stock exchange monitor with index information.]
Torsten Asmus

The semi-annual rebalancing of U.S. equities is officially underway after FTSE Russell unveiled its preliminary list of shifts for the broad-market Russell 3000 Index on Monday.

Highlighting a major sector realignment across the healthcare and biotech landscapes:

*
EXPECTED ADDITIONS: Ocugen (OCGN [https://seekingalpha.com/symbol/OCGN]), Senseonics (SENS [https://seekingalpha.com/symbol/SENS]), Nektar Therapeutics (NKTR [https://seekingalpha.com/symbol/NKTR]), Agenus (AGEN [https://seekingalpha.com/symbol/AGEN]), and CytomX Therapeutics (CTMX [https://seekingalpha.com/symbol/CTMX]).

*
EXPECTED DELETIONS: Nano-X Imaging (NNOX [https://seekingalpha.com/symbol/NNOX]), Tvardi Therapeutics (TVRD [https://seekingalpha.com/symbol/TVRD]), Fate Therapeutics (FATE [https://seekingalpha.com/symbol/FATE]), Quantum-Si Incorporated (QSI [https://seekingalpha.com/symbol/QSI]), and Cardiff Oncology (CRDF [https://seekingalpha.com/symbol/CRDF]).

This year's historic structural changes will officially take effect following the close of U.S. equity markets on Friday, June 26.

MORE ON THE TOP CONSTITUENTS OF THE RUSSELL 3000 INDEX

* Quantum-Si incorporated (QSI) Shareholder/Analyst Call Prepared Remarks Transcript [https://seekingalpha.com/article/4905372-quantum-si-incorporated-qsi-shareholder-analyst-call-prepared-remarks-transcript]
* Fate: 'Hold' FT819 Regimen B Dosing And Potential FDA Alignment In H2 2026 [https://seekingalpha.com/article/4903350-fate-hold-ft819-regimen-b-dosing-and-potential-fda-alignment-in-h2-2026]
* Nano-X Imaging: Too Cheap To Ignore, Too Early To Buy [https://seekingalpha.com/article/4903064-nano-x-imaging-too-cheap-to-ignore-too-early-to-buy]
* Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit [https://seekingalpha.com/news/4596692-ocugen-assertio-among-healthcare-stocks-set-to-join-russell-microcap-definium-therapeutics-tvardi-therapeutics-to-exit]
* Cardiff Oncology GAAP EPS of -$0.18 misses by $0.05, revenue of $0.04M misses by $0.04M [https://seekingalpha.com/news/4593304-cardiff-oncology-gaap-eps-of-0_18-misses-by-0_05-revenue-of-0_04m-misses-by-0_04m]